img__amixin_blue_pack--left_turn.jpeg

39.00$

Category:

Product Description

img__amixin_blue_pack--left_turn.jpeg

FREE SHIPPING TO ALL COUNTRIES!!!

I  ACCEPT  PAYPAL

SHIPPING:
Europe delivered time is 8 — 12 business days.

Usa/canada delivered time 15-20 business days.

Australia/Asia delivered time 15-26 business days.

For any possible questions, please, contact me!
NEW
100 % ORIGINAL
TRACKING NUMBER
THANK YOU FOR VISITING MY LOT
It is very important !!! Item will be shipped from Russia for 2-3 days and free shipping takes 14 to 21 days

Free shipping

NEW
100 % ORIGINAL

TRACKING NUMBER

THANK YOU FOR VISITING MY LOT

The antiviral and immunomodulatory drug. Inductor synthesis of interferon
dosage form
Tablets, film-coated orange, round, biconcave. At the turn of orange, allowed minor blotches of orange and white.
Composition
tilorona (tilaksin) 125 mg

Excipients: potato starch, microcrystalline cellulose, povidone (Kollidon 30), calcium stearate, sodium Valium (primelloza).

Cover structure: Valium (hydroxypropyl methylcellulose), titanium dioxide, macrogol 4000 (polyethylene glycol 4000), polysorbate 80 (Tween 80), quinoline yellow (E104), yellow-orange sikovit 85 (E110).
pharmachologic effect
The low molecular weight synthetic inducer of interferon, which stimulates the body’s interferon alpha, beta, gamma. The basic structures producing interferon in response to tilorona are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils, and granulocytes. After taking the drug inside a maximum production of interferon is defined in the sequence gut-liver-blood through the 4-24 hours. Amixin® has immunomodulatory and antiviral effect.

In human leukocytes induces the synthesis of interferon. It stimulates bone marrow stem cells, in a dose dependent increases antibody reduces the degree of immunosuppression, restores ratio T-suppressor and T-helper cells. Effective with various viral infections (including those caused by influenza viruses, other pathogens of acute respiratory viral infections, hepatitis viruses, herpes). The mechanism of antiviral action due to inhibition of translation of virus-specific proteins in the infected cells, whereby virus replication is inhibited.
Pharmacokinetics
Suction

After taking the drug inside tilorona it is rapidly absorbed from the gastrointestinal tract. Bioavailability is about 60%.

Distribution

Binding to plasma proteins — about 80%.

Metabolism and excretion

Tilorona no biotransformation and accumulates in the body. Displayed virtually unchanged in the feces (approximately 70%) and urine (about 9%). T1 / 2 is 48 h.
Side effects
From the digestive system: dyspepsia symptoms.

Other: possible intermittent fever, allergic reactions.
sale Properties
No prescription
Special conditions
Amixin® compatible with conventional antibiotic agents and the treatment of viral and bacterial infections.
testimony
adults

— For the prevention and treatment of influenza and SARS;

— For the treatment of viral hepatitis A, B and C;

— For the treatment of herpes infections;

— For the treatment of cytomegalovirus infection;

— In the complex therapy of allergic and viral encephalomyelitis (including multiple sclerosis, leykoentsefality, uveoentsefality);

— In the complex therapy of urogenital and respiratory chlamydia;

— In the complex treatment of pulmonary tuberculosis.

In children older than 7 years

— For the treatment of influenza and SARS.
Contraindications
— Pregnancy;

— The period of breast-feeding;

— Children up to age 7 years;

— Hypersensitivity to the drug.
Dosage
Amiksin Inside, after a meal. For children older than 7 years old: In uncomplicated forms of influenza and other acute respiratory viral infections — 60 mg 1 time per day on the 1st, 2nd and 4th day from the beginning of treatment. Heading dose — 180 mg (3 tablets). In the event of complications of influenza and other acute respiratory viral infections — 60 mg 1 time a day for 1 st, 2 nd, 4 th and 6 th day from the start of treatment. Heading dose — 240 mg (4 tablets). For adults (over 18 years): For treatment of influenza and other acute respiratory viral infections — 125 mg of the first 2 days of treatment per day, then 125 mg every 48 hours. In the course — 750 mg (6 tablets). For the prevention of influenza and other acute respiratory viral infections — 125 mg 1 time per week for 6 weeks. In the course — 750 mg (6 tablets). For treating herpes, cytomegalovirus infection — the first two days of 125 mg, followed 48 hours later by 125 mg. Heading dose — 1.25-2.5 g (10-20 tablets). For non-specific prevention of hepatitis A — 125 mg 1 time per week for 6 weeks. For the treatment of viral hepatitis A — on the first day of 125 mg 2 times, then 125 mg every 48 hours for the course -. 1.25 g (10 tablets). For the treatment of acute hepatitis B — the first two days at 125 mg then 125 mg every 48 hours for treatment — 2 g (16 tablets). In protracted course of hepatitis B — 125 mg 2 times a day on the first day, followed by 125 mg every 48 hours. In the course of treatment — 2.5 g (20 tablets). In chronic hepatitis B — initial phase of treatment (2.5 g — 20 tablets) — the first two days with 125 mg 2 times a day, and then 125 mg every 48 hours. Continuation phase (1.25 g — 10 2.5 g tablet — 20 tablets) — 125 mg per week. Heading dose Amiksina® from 3.75 g to 5 g, duration of treatment 3,5-6 months, depending on the results of biochemical, immunological, morphological studies, reflecting the degree of activity of the process. In acute hepatitis C — 125 mg per day in the first 2 days of treatment followed by 125 mg every 48 hours. Treatments — 2.5 g (20 tablets). In chronic hepatitis C — initial phase of treatment (2.5 g — 20 tablets) — the first two days with 125 mg 2 times a day, and then 125 mg every 48 hours. Continuation phase (2.5 g — 20 tablets) — 125 mg per week. Heading dose Amiksina® — 5 g, duration of treatment — 6 months depending on the results of biochemical, immunological, morphological markers of activity of the process. When combined therapy neyrovirusnyh infections — 125-250 mg per day the first 2 days of treatment, followed by 125 mg every 48 hours. Dose set individually, a course of treatment for 3-4 weeks. When urogenital and respiratory chlamydia — the first two days of 125 mg, followed 48 hours later by 125 mg. Heading dose — 1.25 g (10 tablets). When the complex treatment of pulmonary tuberculosis — 250 mg of the first two days of treatment, followed by 125 mg every 48 hours. Course dose — 2.5 grams (20 tablets).